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We surveyed the scientiﬁc literature regarding amyotrophic lateral sclerosis, the SOD1 mouse model,
complex adaptive systems, evolution, drug development, animal models, and philosophy of science in an
attempt to analyze the SOD1 mouse model of amyotrophic lateral sclerosis in the context of evolved
complex adaptive systems.
Humans and animals are examples of evolved complex adaptive systems. It is difﬁcult to predict the
outcome from perturbations to such systems because of the characteristics of complex systems.
Modeling even one complex adaptive system in order to predict outcomes from perturbations is difﬁcult.
Predicting outcomes to one evolved complex adaptive system based on outcomes from a second,
especially when the perturbation occurs at higher levels of organization, is even more problematic. Using
animal models to predict human outcomes to perturbations such as disease and drugs should have a very
low predictive value. We present empirical evidence conﬁrming this and suggest a theory to explain this
phenomenon. We analyze the SOD1 mouse model of amyotrophic lateral sclerosis in order to illustrate
this position.
 2013 The Authors. Published by Elsevier Ltd. Open access under CC BY-NC-SA license.Contents
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In this essay, we will examine animal models when they are
used to predict human response to drugs and disease (We realize
humans are animals, but for convenience will use the term animal
to mean nonhuman animal.). We readily acknowledge that animal
models can be used in other, nonpredictive, ways as well (see cat-
egories 3e9 in Table 1). For example, animals can be successfully license.
Table 1
Nine categories of animal use in science and research (Greek and Shanks, 2009).
1. Animals are used as predictive models of humans for research into such
diseases as cancer and AIDS.
2. Animals are used as predictive models of humans for testing drugs or
other chemicals.
3. Animals are used as “spare parts”, such as when a person receives an
aortic valve from a pig.
4. Animals are used as bioreactors or factories, such as for the production of
insulin or monoclonal antibodies or to maintain the supply of a virus.
5. Animals and animal tissues are used to study basic physiological principles.
6. Animals are used in education to educate and train medical students
and to teach basic principles of anatomy in high school biology classes.
7. Animals are used as a modality for ideas or as a heuristic device, which is a
component of basic science research.
8. Animals are used in research designed to beneﬁt other animals of the same
species or breed.
9. Animals are used in research in order to gain knowledge for knowledge’s
sake.
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ment parts for humans, in comparative research, and as bioreactors.
Models can be classiﬁed in various ways, and the use of model
type varies with purpose. Animal models can also be classiﬁed in
various ways. For example, another method of categorizing animal
models, distinct from Table 1, would be as spontaneous, induced,
transgenic, negative, or orphan models. Hau places all classiﬁcation
schemes in perspective when he states: “The majority of laboratory
animal models are developed and used to study the cause, nature,
and cure of human disorders” [(Hau, 2003) p. 3]. The predictive
value of such models is implied but Hau later states it explicitly:
“A third important group of animal models is employed as predic-
tivemodels. These models are used with the aim of discovering and
quantifying the impact of a treatment, whether this is to cure a
disease or to assess toxicity of a chemical compound.... The
appropriateness of any laboratory animal model will eventually be
judged by its capacity to explain and predict the observed effects in
the target species” (Hau, 2003). Numerous scientists use and pro-
mote animals as predictive models (Gad, 2007; CSPI, 2008; Huff
et al., 2008; Vassar, 2011; Yuen, 2011; Devoy et al., 2012). The
relatively recent categorization of systems into simple, compli-
cated, complex, and chaotic also impacts on the discussion of
models. Complex systems have historically been thought non-
simulable; as a whole, they are difﬁcult if not impossible to model
(Lippman et al., 1995; Bickel and Buhlmann, 1996; Williams, 1997).
With that in mind, what are the implications of modeling one
evolved complex adaptive system (CAS) with another evolved CAS?
Is there predictive value in such modeling and, if so, at what levels
of organization is this possible (Greek and Rice, 2012)?2. Materials and methods
We surveyed the scientiﬁc literature regarding relevant aspects
of amyotrophic lateral sclerosis (ALS), evolved complex adaptive
systems, evolutionary biology, and the SOD1 mouse. We sought to
develop a general theme regarding the use of one CAS (animals) to
model another, similar CAS (humans), and then apply that theme to
the speciﬁc case of the SOD1 mouse as a model for human ALS. For
this evaluation we needed to understand how evolution has acted
on CASs, as one reason species differ is because each has taken a
different evolutionary trajectory. We sought to understand how the
evolutionary process has resulted in CASs that are differently com-
plex. This led us to genetics, evolutionary and developmental
biology (evo devo), regulation and expression of genes, gene net-
works, and convergent evolution, as well as other areas. We thenattempted to place these genetic changes in the context of
complexity science and discovered that the various properties of
CASs, and hence outcomes to perturbations, are greatly inﬂuenced
by the genetic changes that cause the evolutionary process. This led
us to study how animal models are employed in biomedical science
and what the term predict means in biomedical science.
3. Results and discussion
3.1. Complexity science
We beginwith an overview of complex systems. Various aspects
complex systems and of modeling complex systems have been
addressed in this journal and we refer the reader to these studies,
including (Miquel, 2011; Soto et al., 2011; Bard et al., 2012a,b;
Durrive, 2012; Melham, 2012; Melham et al., 2012; Bizzarri et al.,
2013; Gare, 2013; Nakajima, 2013; Schroederc, 2013).) The study
of CASs occurs in many disciplines of science, mathematics, and
engineering (Northrop, 2011). Northrop deﬁnes a system as “a
group of interacting, interrelated, or interdependent elements (also
agents, entities, parts, states) forming or regarded as forming a
collective entity” [(Northrop, 2011) p. 2]. Northrop deﬁnes
complexity as: “a subjective measure of the difﬁculty in describing
and modeling a system (thing or process), and thus being able to
predict its behavior” (Northrop, 2011) (Emphasis added.). Systems,
likemodels, can be categorized using various criteria. For example a
system can be understood intuitively or need deeper examination.
Similarly, a system can demonstrate linearity or nonlinearity
(Northrop, 2011). Braithwaite was conscious of such problems with
models, warning that “The price of employment of models is
eternal vigilance” (Braithwaite, 1953). Characteristics of complex
systems that result in modeling difﬁculties include the following.
A complex system is composed of many components that exist
on various scales. Some of these components are simple systems
(electrons and atoms) but others are complex (gene networks, the
immune system, and organs). A CAS is a system of systems. At the
lower levels of organization, the parts are interchangeable: an
electron can replace another electron and an atom can replace
another atom (provided it is the same element). But at higher levels
of organization, the parts are not interchangeable. A heart from a
monkey cannot replace a heart from a human, ceteris paribus. Alex
Novikoff explained this in 1947: “What are wholes on one level
become parts on a higher one... both parts and wholes are material
entities, and integration results from the interaction of parts as a
consequence of their properties.” Novikoff observes that some
systems must be studied as whole intact entities because living
organisms are not “machines made of a multitude of discrete parts
(physico-chemical units), removable like pistons of an engine and
capable of description without regard to the system from which
they are removed” [(Mayr, 1998) p. 18]. One must appreciate the
interactions of the parts because, according to Mayr, “a description
of the isolated parts fails to convey the properties of the system as a
whole. It is the organization of these parts that controls the entire
system” [(Mayr, 1998) p. 18].
These components can be grouped into modules that commu-
nicate with each other. But the modules may respond differently to
the same perturbation. There is a hierarchy of organization among
the parts and modules. The upper levels are above the lower levels,
and are usually composed of the lower levels; thus there is asym-
metry in the relationship between upper and lower levels. More-
over, a component or module may be in several different
hierarchies (Ahl and Allen, 1996).
A complex system has feedback loops between components and
modules. These feedback loops can inhibit or amplify a response
(Kastens et al., 2009).
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such as the genetic make-up with which an individual is born.
Complex systems may demonstrate chaotic behavior and exhibit a
“non-Gaussian distribution of outputs” (Kastens et al., 2009).
A perturbation to the system may have unintended, unanticipated
effects far removed from the subsystem ormodule initially affected.
Complex systems demonstrate nonlinearity, self-organization,
and are dynamic; they communicate with their environment. This
may lead to epigenetic changes in the case of animals and humans.
Complex systems demonstrate redundancy of components as well
as robustness d the capacity to resist change. This can be illus-
trated by the fact that knocking out a gene may produce no
noticeable effects in one strain of mousewhile it is lethal to another
strain (Morange, 2001; Pearson, 2002; Belmaker et al., 2012). Other
examples would be gene pleiotropy d when one gene inﬂuences
multiple traits d such as involvement in multiple diseases. An
example of multiple diseases sharing the same genes would be
attention deﬁcit-hyperactivity disorder (ADHD), autism, bipolar
disorder, major depressive disorder, and schizophrenia, which
share four genes (Cross-Disorder Group Of The Psychiatric
Genomics Consortium, 2013). This can occur when one gene
makes multiple proteins through alternative splicing (Hodgkin,
1998), or simply as a consequence of one protein.
Complex systems are more than the sum of their parts. Wil-
liams deﬁnes a complex system thusly: “A system is a collection
of interacting elements. Behavior of the system is distinct from
the behavior of its parts or elements. Output is not proportional
to input and output to a perturbation may vary over time”
(Williams, 1997). The parts of a complex system are important,
but knowledge of the interactions of the parts is also vital for
understanding a CAS. This limits what can be learned about CASs
through reductionism. CASs demonstrate emergent phenome-
non. Therefore the system cannot be fully understood even with
total knowledge of its parts. This also limits what can be learned
about CASs through reductionism. A complex system has the
ability “to switch between different modes of behavior as the
environmental conditions are varied.” It is adaptive (Nicolis and
Prigogine, 1977). CASs as a whole are not thought to be simu-
lable (Lippman et al., 1995; Bickel and Buhlmann, 1996; Williams,
1997). Work on mathematical modeling is challenging this,
however.
Besides living systems, other examples of complex systems
include ecosystems, climate, and the global economy (Kastens et al.,
2009). For more on the characteristics and implications of CASs see
previously mentioned references in this journal as well as Novikoff,
1945; Nicolis and Prigogine, 1977; Horgan, 1995; Lewin, 1999;
Lombardi, 2000; Seely and Christou, 2000; Goodwin, 2001;
Manson, 2001; Noble, 2001; Aird, 2002; Csete and Doyle, 2002;
Kitano, 2002b; Sole and Goodwin, 2002; Alm and Arkin, 2003;
Ottino, 2004; Noble, 2008; and Bizzarri et al., 2013.
The above characteristics are problematic in terms of studying
CASs via reductionism. Mayr deﬁnes reductionism as “The belief
that the higher levels of integration of a complex system can be
fully explained through a knowledge of the smallest components”
[(Mayr, 2002) p. 290]. Reductionism has been extremely effective
for studying simple, nonliving systems and even for studying some
aspects of CASs, such as outcomes at the lower levels of organiza-
tion. But reductionism cannot explain the totality of a CAS. For an
evolved, living CAS to be fully understood, the whole must be
studied as a whole (Van Regenmortel, 2002a,b,c, 2004a,b, 2012;
Van Regenmortel and Hull, 2002). Bizzarri et al., state: “complex
systems exhibit properties and behavior that cannot be understood
from laws governing the microscopic parts given that such systems
cannot be easily ‘reduced’ or explained by simple deterministic
rules” (Bizzarri et al., 2013).Gould wrote in 2001: “the collapse of the doctrine of one gene
for one protein, and one direction of causal ﬂow from basic codes to
elaborate totally marks the failure of reductionism for the complex
system that we call biology” (Gould, 2001). Even gene function is
not deterministic as gene expression has stochastic aspects within a
single cell, in addition, inter-species differences, and even intra-
strain differences, are manifest in gene function (Morange, 2001;
Elowitz et al., 2002; Pearson, 2002; Gibbs et al., 2007; Holmes,
2007; Belmaker et al., 2012; Bizzarri et al., 2013). Stochasticity is
also an aspect of gene networks (Becskei and Serrano, 2000) and
proteineprotein interactions (Kupiec, 2010). Moreover, cause and
effect has been replaced by a causal chain thus limiting the role of
reductionism even further. Thus, complex systems are examples of
nonlinear dynamic systems and their behavior is best modeled by
partial differential equations (Noble, 2001, 2008; Kurakin, 2005;
Moss, 2006).
Van Regenmortel supports this, stating: “Another defect of
reductionist thinking is that it analyses complex network in-
teractions in terms of simple causal chains andmechanistic models.
This overlooks the fact that any clinical state is the end result of
many biochemical pathways and networks, and fails to appreciate
that diseases result from alterations to complex systems of ho-
meostasis” (Van Regenmortel, 2004b). Similarly, Mazzocchi ex-
plains: “Inmodern science reductionism is usually combinedwith a
linear and simplistic idea of causality, where the focus is restricted
to the role of a single or few essential causes or factors (occurring at
the fundamental physical level), and with determinism. This is the
ideawhereby any phenomenon in nature is completely determined
by pre-existing causes to which it is bound by a relationship of
necessity, and that only one possible future exists. Determinism
entails the predictability of the evolution of a system, which can be
completely established by knowing the initial conditions and the
mechanical laws governing its behavior...” (Mazzocchi, 2012).
Even linear systems are not as predictable as many suppose. For
example, the three-body problem led to the development of Chaos
Theory (Boyd and Mcmillan, 1992; Barrow-Green, 1997). Ironically,
Bohm noted in 1969 that physics was abandoning the reductionism
is everything mentality while biology was embracing it (Bohm,
1969). The realization that reductionism is insufﬁcient for study-
ing complex systems has led to a systems-oriented approach in the
biological sciences, known as systems biology (Kitano, 2002a,b,
2007; Noble, 2008; Bard et al., 2012a,b; Melham et al., 2012;
Werner, 2012) (see Table 2 [Ahn et al., 2006]).
Some would argue that the human brain is the most complex
system known as well as the most difﬁcult to study. Novella stated:
“There are approximately 100 billion neurons in the adult human
brain. Each neuron makes thousands of connections to other neu-
rons, resulting in an approximate 150 trillion connections in the
human brain. The pattern of those connections is largely respon-
sible for the functionality of the braind everything we sense, feel,
think, and do” (Novella, 2011). We see the same problems in
studying other complex systems. Koch describes the complexity of
the human brain and explains why studying complex systems is
difﬁcult: “Such systems are characterized by large numbers of
highly heterogenous components, be they genes, proteins, or cells.
These components interact causally in myriad ways across a very
large spectrum of spaceetime, from nanometers to meters and
from microseconds to years. A complete understanding of these
systems demands that a large fraction of these interactions be
experimentally or computationally probed. This is very difﬁcult...
ﬁelds as diverse as neuroscience and cancer biology have proven
resistant to facile predictions about imminent practical applica-
tions. Improved technologies for observing and probing biological
systems have only led to discoveries of further levels of complexity
that need to be dealt with. This process has not yet run its course.
Table 2
Reductionism versus a systems-oriented perspective (Ahn et al., 2006).
Characteristic Reductionism Systems-oriented approach
Principle Behavior of a biological system can be explained by the
properties of its constituent parts
Biological systems posses emergent properties that are only
possessed by the system as a whole and not by any isolated
part of the system
Metaphor Machine, magic bullet Network
Approach One factor is singled out for attention and is given
explanatory weight on its own
Many factors are simultaneously evaluated to assess the
dynamics of the system
Critical factors Predictors/associated factors Time, space, content
Model characteristics Linear, predictable, frequently deterministic Nonlinear, sensitive to initial condition, stochastic (probabilistic), chaotic
Medical concepts Health is normalcy
Health is risk reduction
Health is homeostasis
Health is robustness
Health is adaptation/plasticity
Health is homeodynamics
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brains, and turning this understanding into practical knowledge”
(Koch, 2012).
Northrop addresses the question of why complex systems are
so difﬁcult for humans to comprehend. He begins by reminding us
that Homo sapiens are not that far removed from our huntere
gatherer ancestors. We evolved to confront simple problems
(a predator, for instance) that usually had simple solutions (move
away from the predator). Today we try to resolve problems
involving complex systems by assuming there is a simple, single
point of contact solution, which we can ascertain using intuition
and reductionism. This approach is obviously inadequate. Like-
wise, we seek solutions based on intervening in one variable
when complex systems should be examined in terms of a causal
chain and multiple inputs. We need training in order to under-
stand the problems associated with complex systems and
appreciate threats that involve complex systems (Northrop, 2011).
Wolkenhauer et al., summarized ﬁndings from a series of work-
shops that led to publication of Science Policy Brieﬁng (SPB) Nr.
35. and reinforced Northrop stating: “Conventional modes of
medical and biological explanation rely primarily on verbal
reasoning and are only suited for dealing with mechanisms that
involve small numbers of components and short chains of cau-
sality. The diseases most relevant for humankind, however,
involve a large number and variety of components interacting
through complex networks. New approaches are therefore
required to fuel further advances in modern medicine”
(Wolkenhauer et al., 2009). Wolkenhauer et al., report that the
workshops recommended a systems biology approach and state:
“A major breakthrough in systems biology is imminentdmedical
research is at the crossroads; conventional approaches will no
longer work” (Wolkenhauer et al., 2009). They then chastise
medical science for not keeping up with times:
 While the need for mathematical modeling and interdisci-
plinary collaborations is becoming widely recognised in the
biological sciences, with substantial implications for the
training and research fundingmechanismswithin this area, the
medical sciences have yet to follow this lead.
 To achieve major breakthroughs in Medical Systems Biology,
existing academic funding schemes for large-scale projects
need to be reconsidered.
 The hesitant stance of the pharmaceutical industry towards
major investment in systems biology research has to be
addressed.
 Leading medical journals should be encouraged to promote
mathematical modeling (Wolkenhauer et al., 2009).
Much remains to be sorted out in terms of research on and for
evolved complex systems (Luttge, 2012).Koch discusses modeling a complex system with a digital
computer (Koch, 2012). For a system with 3 components, the Bell’s
number (B) would be 5. The interactions scale up at a rate that
exceeds exponentially. For example, B10¼ 115,975 (log (Bn)z n[log
(n)  1]). Koch states that even assuming Moore’s law continues to
hold true, in “a neural synapse d the presynaptic terminal has an
estimated 1000 distinct proteins. Fully analyzing their possible
interactions would take about 2000 years. Or consider the task of
fully characterizing the visual cortex of the mouse d about 2
million neurons... will take about 10 million years” (Koch, 2012)
(see Fig. 1). Koch concludes: “Given the large number of compo-
nents that cannot be averaged away, any possible technological
advance is overwhelmed by the relentless growth of interactions
among all components of the system. It is not feasible to under-
stand evolved organisms by exhaustively cataloging all interactions
in a comprehensive, bottom-up manner. More is needed” (Koch,
2012).
Koch then describes the idea of Allen and Greeves (2011) who
introduced the term “complexity brake” to explain why diverse
ﬁelds are not amenable to prediction. Their premise is that the
more we learn regarding complex systems the more we ﬁnd that
deeper levels exist and this places a brake on how much we can
understand about complex systems. The complex systems we un-
derstand have a limited number of interactions among compo-
nents. Living complex systems do not follow this “limited number”
rule.
Predicting an outcome to a perturbation to a CAS is very difﬁcult,
and using one CAS in order to predict outcomes for a second is even
more difﬁcult, if not impossible, when the level of examination is
not in the realm of some of the simple systems that comprise a CAS.
The history of cancer research is but one example of the failure of
reductionism vis-à-vis animal models. When attempting to predict
human response to chemicals d be they carcinogens or chemo-
therapy d using reductionism-based animal models, the failures
have been epic (Heng, 2008; Brennan et al., 2010; Editorial, 2006,
2011a,b; Cook et al., 2012; Corry, 1952; Smith et al., 1965;
Clemmensen and Hjalgrim-Jensen, 1980; Salsburg, 1983; Di Carlo,
1984; Ennever et al., 1987; Marsoni et al., 1987; Stoloff, 1992;
Beniashvili, 1994; Gura, 1997; Kleinman, 1997; Dybing and Sanner,
1999; Rohan et al., 2000; Habeck, 2002; Hahn et al., 2002;
Rangarajan and Weinberg, 2003; Kamb, 2005; Dimasi and
Grabowski, 2007; Kummar et al., 2007; Dimasi et al., 2010;
Arrowsmith, 2011b; Caponigro et al., 2011; Oreskes and Conway,
2011; Begley and Ellis, 2012; Greek, 2013b). Hochachka and Som-
ero summarized the problem with studying complex systems by
comparing humans with chimpanzees. They stated that although
humans and chimps share 99% of their amino acid sequences, the
two species are very different. What accounts for the differences?
Hochachka and Somero state: “only exceedingly minimal changes
in genome sequences may be necessary to specify separate species,
Fig. 1. How long will it take? The logarithm of Bell’s number (left axis) and the upper
bound on the time it takes to fully analyze all possible partitions of the system (right
axis) are shown as a function of the number of components (proteins or cells) (Koch,
2012).
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Fig. 2. Dynamics of evolved complex adaptive systems. Each of the tools below
employed by evolution is a component or module in a complex system. The changes
caused by evolution will affect the CAS in a nonlinear fashion. The differences among
species include all of the below. The thousands of differences between two species
result in a species that is differently complex from its ancestors and cousins.
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terns” (Hochachka and Somero, 2002). We should not expect pre-
dictive value from modeling one CAS with another that has major
genetic differences.
We now turn to the genetics and mechanisms used by the
process of evolution that resulted in systems that are differently
complex.3.2. Evolved complex systems
In this article, we are concerned with the use of one evolved CAS
to predict drug and disease response in another evolved CAS. In this
sectionwewill discuss what tools the process of evolution has used
in speciation and why these are important to our discussion.
Dobzhansky states: “Nothing in biology makes sense except in
the light of evolution” (Dobzhansky, 1973). The process of evolution
has produced the many species we see today and many more that
are now extinct. Put simply, evolution is a change in allele fre-
quency over time (an allele being one form of the same gene).
Though how evolution accomplishes this is anything but simple.
When one nucleotide is wrong, the change is called single nucle-
otide polymorphism (SNP). SNPs are responsible for sickle cell
anemia and cystic ﬁbrosis, among other diseases. Because of dif-
ferences like SNPs, not all children may be protected by the same
vaccine (Yucesoy et al., 2009). Likewise, the bar-headed goose
(Anser indicus) is very similar to the Greylag goose (Anser anser),
however the bar-headed goose possesses high-altitude
(>30,000 ft) hypoxia adaptation due to a difference in the hemo-
globins of the two species involving only four amino acids. Besides
SNPs, organisms can change due to other mutations in the genes
such as: deletions of chromosomes, genes, or nucleotides; in-
sertions of chromosomes, genes, or nucleotides; inversions, dupli-
cations, and copy number variants (CNVs) of genes. See Fig. 2 for
other tools used by evolution. CNVs are especially important in the
metabolism of drugs. If one individual has one copy of a gene that
makes a drug metabolizing enzyme (DME) while another has ﬁve
copies, the dose will need to be adjusted markedly. What all of
these genetic changes have in common is the fact that seemingly
small variations can result in dramatically different outcomes to
perturbations. Extensive variations simply increase the likelihood
of different outcomes.
Perhaps the most important tool in evolution’s toolkit is gene
regulation and expression. For example, Seok et al., reported that
mice and humans were studied for gene response to sepsis, burns,and trauma (Seok et al., 2013). The authors were inspired to
conduct the study in part because at least 150 drugs have been
shown efﬁcacious for sepsis in mice but have failed in humans.
Seok et al., discovered that the genes involved in the human reac-
tion to these inﬂammatory processes d the genes expressed d
were different from the ones activated in mice under similar con-
ditions (see Fig. 3). Dolgin quantiﬁes the magnitude of these failed
animal models for sepsis: “despite the fact that some compounds
have repeatedly reversed the symptoms of sepsis in animal tests,
not a single drug has proven effective in human clinical trials, even
though more than 30,000 people have been included in random-
ized control studies involving candidate antisepsis agents over the
past 25 years (see (News, 2012))” (Dolgin, 2013).
By regulating and expressing genes differently, the same genes
could be used to make two different species. This can be illustrated
by the caterpillar and the butterﬂy, although, of course, they are not
two different species. The same genes are involved in making both
the caterpillar and the butterﬂy, but the two look nothing alike. This
is due to the timing of when the genes are turned on or off, and in
what proportions they are expressed in the various tissues. Another
example would be the development of mice and humans. Each has
approximately the same number of genes, with each differing from
the other in about 300 genes. Yet the gene that makes a tail in the
mouse is turned off in humans during embryogenesis, thus humans
have no tail (though exceptions do occur). Venter stated that one
could make almost any of the higher vertebrates using the same
genes (Cohen and Coghlan, 2001). The notion that regulatory genes
are responsible for major changes during evolution is now more or
less universally accepted (Lowe et al., 2011). An example of regu-
latory differences would be that humans have lost 510 sections of
regulatory DNA that are vital in other animals, including chim-
panzees (Mclean et al., 2011). For more on gene regulation see
Ptashne and Gann, 2002; Kirschner and Gerhart, 2006.
Genes also work in networks, which allows for even more
variation. If we assume a 100-gene network with each gene
switched off or on, then the number of states in which the network
Fig. 3. Comparative gene changes. Pathway comparisons between the human burns, trauma, and endotoxin and mouse models. Shown are bar graphs of Pearson correlations (R2)
for the ﬁve most activated and suppressed pathways between the four model systems (human endotoxemia and the three murine models) vs. human trauma and burns. Negative
correlations are shown as negative numbers (R2). Human burn is shown as the reference. In every pathway, human endotoxemia had much higher similarity to human injury than
mouse models (Seok et al., 2013).
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some sequence and stayed in that state for one microsecond, it
would take billions of billions of years to get through all the states
(Goodwin, 2001). Humans have in the neighborhood of 20,000
genes that can be expressed between 0 and 1.0 giving a number of
states of at least 220,000. With 24,000 genes, even a pairwise matrix
would yield 576 million combinations. Other networks include
geneeprotein networks and protein networks. This should give
some idea of the complexity of the system and why small changes
in it can have enormous implications (for examples, see Table 3 and
Fig. 4).
The above is not to imply that a single gene is unimportant.
Bakircioglu et al., discovered that the size and shape of the human
cerebral cortex (the outer most layer of the brain) appears to be due
to changes in just one gene (Bakircioglu et al., 2011).
Bakircioglu et al., arrived at this conclusion after studying three
families that have children with very small brains: microcephaly.
The children’s brains were about 10% of normal size. Mutations in
the gene NDE1 appear to be responsible. This could mean that the
difference between the human cerebral cortex and the cerebral
cortex of animals is due to this one gene.
Mazzocchi describes the problem of molecular biologists treat-
ing evolved CASs as simple systems (Mazzocchi, 2012). When
knocking genes out of mice, one can see various effects from de-
leting the same gene. In part, this is because the gene acts in a
“complex macromolecular organization. Gene and their productsdo not exist and operate, in fact, as isolated and autonomous en-
tities.” Proteins also act in networks, and these networks are also
complex systems. The full effect of these genes is only appreciated
at higher levels of organization. Since CASs exhibit redundancy,
such as when gene function is duplicated by other genes, knocking
out a gene may lead to no changes in one CAS but be lethal in
another. Mazzocchi continues: “Intracellular-signaling networks,
initially seen as simple unidirectional pathways, have progressively
revealed their complexity. They are now seen as compounded by a
multitude of molecular components, which interact in many
complex ways, including feedback mechanisms. This implies that
[it] is often impossible to predict the effects of their modiﬁcation”
(Mazzocchi, 2012).
Jacques Monod famously stated: “What is true of Escherichia coli
is also true of the elephant.” Unfortunately, Monod was not entirely
correct in this. It is true that on the gross morphological level all
mammals have hearts, livers, and lungs that perform more or less
the same function, that all life is composed of conserved processes,
and that the fundamental building blocks of matter are the same.
However, at higher levels of organization, or when one delves
deeper into the details of conserved processes, tissues, organs, and
even biochemistry, there are very important differences. These
differences in CASs account for the dissimilarities in response to
drugs and disease (Greek and Rice, 2012).
We should take a moment to point out the importance of
convergent evolution in this discussion. Organisms can arrive at the
Table 3
Differences between humans and apes in incidence or severity of medical conditions
(Varki and Altheide, 2005).
Medical condition Humans Great apes
Deﬁnite
HIV progression to AIDS Common Very rare
Hepatitis B/C late complications Moderate to severe Mild
P. falciporum malaria Susceptible Resistant
Myocardial infarction Common Very rare
Endemic infectious retroviruses Rare Common
Inﬂuenza A symptomatology Moderate to severe Mild
Probable
Menopause Universal Rare?
Alzheimer’s disease pathology Complete No neuroﬁbrillary
tangles
Epithelial cancers Common Rare?
Atherosclerotic strokes Common Rare?
Hydatiform molar pregnancy Common Rare?
Possible
Rheumatoid arthritis Common Rare?
Endometriosis Common Rare?
Toxemia of pregnancy Common Rate?
Early fetal wastage (aneuploidy) Common Rare?
Bronchial asthma Common Rare?
Autoimmune diseases Common Rare?
Major psychoses Common Rare?
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anisms. The current Metazoa provides numerous instances of this.
For example, the eyes of humans and octopi resemble each other on
the gross morphological scale but the wiring is distinctly different
[(Kirschner and Gerhart, 2006) pp. 240e1]. Different species of batsFig. 4. Disease networksdeveloped different mechanisms by which they now drink nectar
(Davalos et al., 2012). Blond hair evolved in Melanesians by a
different mechanism than it did in Europeans (Kenny et al., 2012).
Ion selectivity in neuronal signaling channels (Gur Barzilai et al.,
2012), and clot degradation (Bugge et al., 1996) are other exam-
ples of traits that evolved convergently in different animals. Spindle
neurons have arisen independently in species as diverse as humans
and cetaceans. Spindle neurons, which connect parts of the brain
involved in higher cognition, were once thought to only occur in
primates, but they also exist in cetaceans, such as humpback
whales and ﬁnwhales, as well as elephants (Holden, 2006; Hof and
Van Der Gucht, 2007; Hakeem et al., 2009).
Shanks and Greek state: “... we note that both Antarctic noto-
thenioids and Arctic cod produce antifreeze glycoproteins that
serve similar functions in the respective organisms. Such proteins
contribute to the ability of these ﬁsh to make a living in their
respective (chilly) positions in the economy of nature. The anti-
freeze glycoproteins are similar in structure and function, but they
nevertheless do not arise from a common gene. Different genes are
involved and this is a case of convergent biochemical evolution
[(Hochachka and Somero, 2002) p. 413]. Similarities can be
deceptive. Thus, similar functions can be achieved through very
different causal pathways” (Shanks and Greek, 2009). Convergent
evolution appears to be ubiquitous in nature, and this limits our
ability to assign genes or mechanisms to traits and expect these
conditions to hold true for every species. Evolution can use the
same parts to make very different organisms. Likewise, it can use
different parts to arrive at the same trait. You cannot examine a trait
or a part in isolation and determine where or how it came into
being. These things must be determined by scientiﬁc study.(Schadt et al., 2005).
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ness makes a better animal model the “modeler’s phylogenetic
fallacy” (Lafollette and Shanks, 1996). Caldwell anticipated the
fallacy and illustrated it thusly: “It has been obvious for some time
that there is generally no evolutionary basis behind the particular-
metabolizing ability of a particular species. Indeed, among rodents
and primates, zoologically closely related species exhibit markedly
different patterns of metabolism” (Caldwell, 1980).
Note that the above does not imply that CASs will always react
differently to the same perturbation. The principles of physics and
geometry, for example, still apply. But the questions biomedical
science is currently asking concern the higher levels of organization
of CASs (see Greek and Rice, 2012 for more on this.). Likewise, while
much was learned in the 1800s by comparative methods of study,
there are several differences between the early study of
morphology and the current study of human disease and drug re-
action. Firstly, very little was known about phylogeny during the
1800s, whereas today much of what can be learned about the gross
similarities among animals and human has been learned. Granted,
there are volumes more vis-à-vis genomics and evo devo left to
discover, but the gross morphological similarities that have his-
torically been discovered by using intact living organisms are
known. This is not an insigniﬁcant point despite its tautological
nature. In any ﬁeld involving comparative anatomy and physiology
the gross morphological commonalities eventually are exhausted
and the research modality must change if more is to be learned in
the most efﬁcient way possible.
A second difference between the 1800s and today is the level of
examination. This returns us to the characteristics of CASs. North-
rop states: “Early bioengineers, biophysicists, and systems physi-
ologists tried to characterize certain physiological regulators as
linear and stationary. Initially, linear systems analysis was inap-
propriately applied to certain complex, physiological regulators and
control systems (e.g., pupil regulation and eye movement control),
which resulted in ‘black-box’ closed-loop models in which linear
transfer functionmodules were connected to a nonlinearmodule in
a single feedback loop. These were phenomenological I/0 models
that gave little insight into the physiology and complexity of the
systems” (Northrop, 2011).
The following from Burggren and Bemis is relevant to our dis-
cussion of animal models: “Yet the use of ‘cockroach as insect,’ ‘frog
as amphibian,’ or ‘the turtle as reptile’ persists, in spite of clear
evidence of the dangers of this approach. Not surprisingly, this type
of comparative physiology has neither contributed much to
evolutionary theories nor drawn upon them to formulate and test
hypotheses in evolutionary physiology” (Burggren and Bemis,
1990). Mazzocchi summarizes the consequences of CASs having
evolved: “What is becoming increasingly acknowledged is that life
cannot be understood fully at the molecular and genetic level”
(Mazzocchi, 2012). Simply knowing that evolved complex systems
are differently complex should inform us to the likelihood that one
evolved CAS will be of predictive value for another in terms of drug
and disease response. We will now examine the empirical
evidence.
3.3. Predictive value of animal models in biomedical science
Before we examine the empirical evidence, we need to deﬁne
predictive value and speciﬁcally how animal models can be assessed
for predictive value. This topic is important because using animal
models in order tomake ourmedications safer andmore efﬁcacious
depends upon the ability of the model to predict human response
to drugs and disease.
The usual story told regarding drug development is that it be-
gins in university laboratories where scientists perform basicresearch using animal models. A pathway is discovered that ap-
pears to contain a target that can be reached by a drug. Note the
adherence to reductionism here. This knowledge is passed on to
Pharma (the pharmaceutical industry), which then develops the
idea, synthesizes chemicals that might bind to the target, and ul-
timately tests the new chemical entity (NCE) on animals, then
humans. The ability of animal models to be of predictive value is
assumed at two points in this process: the identiﬁcation of the
target from animal data, and go-no go decisions regarding the
continuation of development based on tests performed on animals.
If the assumption of predictive value for animal models is false,
then there are scientiﬁc, business, and societal consequences for
using animalmodels. Giles, writing inNature in 2006, states: “In the
contentious world of animal research, one question surfaces time
and again: how useful are animal experiments as a way to prepare
for trials of medical treatments in humans? The issue is crucial, as
public opinion is behind animal research only if it helps develop
better drugs. Consequently, scientists defending animal experi-
ments insist they are essential for safe clinical trials, whereas
animal-rights activists vehemently maintain that they are useless”
(Giles, 2006). An editorial in Nature in 2009 reinforced this posi-
tion: “Animal-research policies need to be guided by a moral
compass d a concensus of what people ﬁnd acceptable and un-
acceptable” (Editorial, 2009). So how much predictive value do
animal models have?
First, we need to analyze the term prediction. The term predict, in
science, does not mean the occasional correct answer, such as: “I
predicted the outcome of the football game.” Guesses that are
sometimes correct but oft times incorrect do not make the person
making the guess a predictive modality or make his opinion one of
predictive value. The same is true for the use of predictions in the
form of scientists generating hypotheses that are then evaluated by
the predictions the hypotheses make and subsequently fulﬁll or fail
to fulﬁll. Science uses a binomial classiﬁcation table and equations
to quantify predictive value, be it from a lab test, research modality,
or other practice (see Table 4). Positive predictive value (PPV)
quantiﬁes the probability that a positive response in the test is a
positive in reality (e.g. a test for cancer is positive and the patient
really has cancer) whereas negative predictive value (NPV) quan-
tiﬁes the probability that negative test equates with a true negative
(if the cancer test is negative, the patient does not have cancer).
Medicine is practiced based on PPVs and NPVs, and these values are
important in other disciplines as well.
We should again point out that not all animal models are used to
predict human response to drugs and disease, and there is scientiﬁc
merit to these other uses (see categories 3e9 in Table 1). However,
we are concerned with the use of animal models for human
response to drugs and disease as they are claimed to be of predic-
tive value: categories 1 and 2 in Table 1. Such claims are plentiful. t
Hart et al., state: “Nonhuman primates (NHPs) are important
models in preclinical research enabling understanding of patho-
genic mechanisms in human disease that readily translate into
therapy development” (t Hart et al., 2012). Cheng states: “Animal
tests are necessary for some research, such as testing drugs for
toxicity. It would be, in my opinion, improper to release drugs for
human use without animal testing” (Gibson, 2012). Vassar states:
“Chronic dosing in mice and monkeys is necessary to show the
efﬁcacy and safety of the antibody before it’s taken into humans”
(Vassar, 2011). Rudczynski wrote in the New Haven Register: “Con-
trary to claims in a letter to the editor, the basic research model
used by Yale University and its peer institutions is scientiﬁcally
valid and predictive of human disease” (Rudczynski, 2011). Yet, the
data do not support these claims.
Data from studies where animal and human outcomes can be
compared reveals that animal models have little predictive value
Table 4
Binomial table and calculations for predictive value.
Gold Standard
GSþ GS
Test Tþ TP FP
T FN TN
Tþ ¼ Test positive
T ¼ Test negative
T ¼ True
F ¼ False
P ¼ Positive
N ¼ Negative
GSþ ¼ Gold standard positive
GS ¼ Gold standard negative
Sensitivity ¼ TP/(TP þ FN)
Speciﬁcity ¼ TN/(FP þ TN)
Positive Predictive Value ¼ TP/(TP þ FP)
Negative Predictive Value ¼ TN/(FN þ TN)
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45, 50, 66e7, 90, 102e3; (Shah et al., 1991; Barber et al., 1992; Scott
et al., 1992; Plos Press Release, 2008), distribution (Fox et al., 1979;
Mahmood, 2000), metabolism (Smith and Caldwell, 1977; Walker
and Mcelligott, 1981; Weatherall, 1982; Bonati et al., 1984;
Abelson, 1992; Caldwell, 1992; Parkinson and Grasso, 1993;
Paxton, 1995; BBC News, 2008; Health Day, 2008; Serrano et al.,
2011), elimination (Sellers et al., 2004; Walton et al., 2004),
toxicity (Litchﬁeld, 1962; Eason et al., 1990; Weaver et al., 2003;
Leaf, 2004; Sankar, 2005; Gad, 2006; Dixit and Boelsterli, 2007;
Hughes, 2008; Plos Press Release, 2008; Sarkar, 2009; Caponigro
et al., 2011; Editors, 2011; Force and Kolaja, 2011; Park et al.,
2011), bioavailability (Sietsema, 1989), carcinogenicity (Tomatis
et al., 1978; Salsburg, 1983; Anisimov et al., 2005), teratogenicity
(Manson and Wise, 1993; Shepard and Lemire, 2004; Greek et al.,
2011b), and efﬁcacy (Johnson et al., 2001; Kola and Landis, 2004;
Suggitt et al., 2005; Hurko, 2006; Albani and Prakken, 2009; Paul
et al., 2010; Arrowsmith, 2011a,b; Buchanan et al., 2011; Cook
et al., 2012; Millan et al., 2012; Morgan et al., 2012). For example,
Suter compared toxicities for ergoloid mesylates, bromocriptine,
ketotifen, cyclosporine, FK 33-824, and clozapine in animals and
humans. The positive predictive value was 0.31, or 31% (Suter,
1990). Pathophysiology for diseases also differ among species
(Paul, 1971; Gross, 1985; Greek and Pound, 2002; Rangarajan and
Weinberg, 2003; Dias et al., 2006; Stump and Vandewoude,
2007; Begley, 2008; Wall and Shani, 2008; Cook et al., 2012; Seok
et al., 2013), although accumulating data for Table 4 is chal-
lenging. However, one indicator of the predictive value is the fre-
quency with which NCEs translate from basic research. Crowley
quantiﬁed this at 0.004% of papers published in the top science
journals (Crowley, 2003). Moreover, the fact that drug targets
identiﬁed in animal models fail so frequently to translate to
humans in drug development (FDA, 2004; Kola and Landis, 2004;
Editorial, 2007; Sarkar, 2009; Paul et al., 2010; Arrowsmith,
2011b; Caponigro et al., 2011; Editorial, 2011b; Begley and Ellis,
2012) is also evidence for questioning the predictive value for
pathophysiology translating to humans.
In light of the ﬁndings above, among scientists conducting
applied research there appears to be consensus on the lack of
predictive value of animal models (Fletcher, 1978; Sietsema, 1989;
Heywood, 1990; Lumley, 1990; Suter, 1990; Horrobin, 2003;
Weaver et al., 2003; Kola and Landis, 2004; FDA, 2009; O’Collins
et al., 2006; Dixit and Boelsterli, 2007; Wall and Shani, 2008;
Greek and Shanks, 2009; Markou et al., 2009; Shanks and Greek,
2009; Shanks et al., 2009; Greek and Greek, 2010; M.E., 2010;
Zielinska, 2010; Collins, 2011; Greek et al., 2011a,b, 2012a; Sharpand Langer, 2011; Cook et al., 2012; Drake III et al., 2012). Despite
this, claims of predictive value are commonly made in grant ap-
plications for what would otherwise be considered basic research.
Roth, in a grant application to NIH, writes: “These data [from
monkeys] will aid in the development of novel strategies for
ameliorating the neurochemical and behavioral deﬁcits in this
potential animal model, and in the cognitive dysfunctions associ-
ated with schizophrenia and other psychiatric disorders” (Roth,
2003). Bankiewicz, in a grant application to NIH, states: “This
work [on monkeys] will provide insight on the mechanisms behind
L-dopa induced dyskinesias and will provide a basis for using gene
therapy approaches to treat patients with Parkinson’s disease”
(Bankiewicz, 2006). Goodlett, also in a grant application to NIH,
writes: “The long-term goals of this component are to use rodent
models of binge alcohol exposure during the 3rd trimester equiv-
alent to screen and identify molecular agents that may be effective
in preventing prenatal alcohol-induced brain damage and neuro-
developmental disorders... A key advantage of integrated ap-
proaches across the Consortium is that as promising candidate
molecular agents emerge, these animal models can provide in vivo
tests of their therapeutic effectiveness” (Goodlett, 2003). These
examples could be easily multiplied.
The writers above are clearly claiming that animal models are of
predictive value for human response to disease and drugs. First,
these claims are inconsistent with the claims for basic research,
which has no goals other than to discover more facts concerning
the material universe (Greek and Greek, 2010). Second, in light of
the fact that even scientists engaging in applied research, vis-à-vis
drug development, acknowledge that animal models have no pre-
dictive value, assigning predictive value to basic research models is
highly suspect. Third, the fact that tax money is being allocated
based onwhat appear to be false claims is a societal concern both in
terms of fraud being committed and in terms of taking research
money from modalities that have a better track record of success
(Rothwell, 2006).
Kirschner addresses the question of improving on drug devel-
opment by predicting efﬁcacy and safety, a current task assigned to
animal models: “The nature of our biological system is that we have
relatively few genesd say 20,000 basic core genesd that are used
over and over again in different contexts. So when we investigate
targets, we need to better appreciate how these function in
different contexts. Moreover, there are many overlapping and
redundant pathways, so we need to better understand genes not as
individual elements with individual functions but within the
context of the circuits in which they operate” (Mullard, 2011). He
then suggests a quantitative wiring diagram and describes a sys-
tems biology approach to drug development. He states: “We need
this kind of investigation, rather than the current approach of
having a hunch, placing a bet and, if the horse doesn’t win, coming
back next week to bet on another race” (Mullard, 2011). Similarly,
the NIH, with whom Kirschner is working, published awhite paper,
“Quantitative and Systems Pharmacology,” calling for a merger of
pharmacology and systems biology (News and Analysis, 2011).
In India, 1725 persons died in clinical drug trials over the four-
year period of 2007e2010 (Tandon, 2011). This is concerning on
many levels. These deaths should inform those in the animal model
community who claim predictive value, in this case the safety of
drugs in clinical trials, for animal models in both applied and basic
research. The predictive value claim for animal models should also
be placed in the context of personalized medicine.
3.4. Personalized medicine
Personalized medicine concerns both current medical practice
and medical research. Physicians have observed very different
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2007). Even monozygotic twins raised in the same environment
do not always suffer from the same diseases or have the same re-
actions to drugs (Javierre et al., 2010a; Misch et al., 2010;
Stankiewicz and Lupski, 2010; Maiti et al., 2011; Ollikainen and
Craig, 2011; Chapman and Hill, 2012; Czyz et al., 2012; Halder
et al., 2012). Differences in disease and drug response also exist
among ethnicities (Gregor and Joffe, 1978; Kalow, 1991; Cheung
et al., 1997; Haiman et al., 2006; Couzin, 2007; Spielman et al.,
2007; Stamer and Stuber, 2007; Kopp et al., 2011; Wilke and
Dolan, 2011), and between the sexes (Holden, 2005; Kaiser, 2005;
Simon, 2005; Willyard, 2009; Klein and Huber, 2010; Wald and
Wu, 2010; Canto et al., 2012). Likewise there is variation among
strains of animals in response to perturbations such as gene
modiﬁcation, drugs, and disease (Morange, 2001; Pearson, 2002;
Belmaker et al., 2012). Most drugs are effective in only approxi-
mately 50% of patients (Roses, 2000). Because of research like the
Human Genome Project, there are now explanations for these dif-
ferences. Drug and disease response has now been linked to speciﬁc
genes. Some cancer patients now have their genome sequenced, as
well as the genome of their cancer, in order to determine treatment
(Daly, 2010) (see Fig. 5 for the goals of personalized medicine.).
Personalized medicine seeks to match drug and disease to in-
dividual patients based on the patient’s genetic make-up. If gene
XZYQ causes adverse side effect A, and the patient has a copy of
XZYQ, then the patient will not be prescribed a drug that triggers
gene XZYQ. Likewise, if gene DACS needs to be present for a drug to
be effective, then only patients with that gene will be given the
drug. Moreover, a disease of the same name does not manifest
exactly the same way in all patients. One group of patients may
experience predominantly renal effects from a certain disease,
while another group may experience cerebral ischemia. DifferentFig. 5. Personalized medicine. Most diseases are heterogenous and the use of mo-
lecular diagnostics can divide them into biological subgroups each with their targets
and drugs (Jørgensen, 2011).drug targets are obviously involved, so different patients will need
different drugs even though they ostensibly have the same disease.
The drugs will be further broken down by genes for side effects.
Hence, per Fig. 5, there will need to be many different types of
drugs to treat the same disease.
We have already covered the reasons for these differences. Small
differences between genomes in the form of CNVs, SNPs, back-
ground genes, modiﬁer genes, and gene regulation among others
result in intra-species differences in outcomes to perturbations.
Because animals are evolved CASs, merely substituting a gene or
even several genes will not be adequate to replicate the disease in
humans. Genes XZYQ and DACS are not pistons that can be
exchanged between systems. In addition, all of this is occurring in a
CAS. Personalized medicine cannot be simulated in a mouse. It is
however, currently available for scores of drugs and diseases
(Meyer, 1990; Kalow, 1991; Gonzalez and Idle, 1994; Nebert, 1997;
Nebert et al., 1999; Bhathena and Spear, 2008; Hughes et al.,
2008; Blair, 2009; Bates, 2010; Dolgin, 2010; Flaherty et al., 2010;
Froehlich et al., 2011; Hudson, 2011; Pirmohamed, 2011; Serrano
et al., 2011; Wang et al., 2011; Belmaker et al., 2012). The contrast
between employing animal models to predict human outcomes
and personalized medicine is stark.
This completes our theoretical examination of using one
evolved CAS to model and predict outcomes to perturbations such
as disease and drugs for another. As we have seen, it is difﬁcult to
predict outcomes for perturbations to single CAS. Using one
evolved CAS in order to predict outcomes for a second that is a
different species seems untenable in light of the proceeding sec-
tions. We now examine a speciﬁc and highly touted animal model.
3.5. The use of the SOD1 mouse to model human ALS
Amyotrophic lateral sclerosis (ALS) is a multifactorial, heterog-
enous group of neurodegenerative diseases characterized by the
selective death of upper motor neurons as well as lower motor
neurons (see Fig. 6) (Rowland and Shneider, 2001; Redler and
Dokholyan, 2012). Described by Charcot in 1865 and 1874
(Charcot, 1865, 1874), ALS is the most common motor neuron dis-
ease and the third most common neurodegenerative disease in the
developedworld (Cleveland and Rothstein, 2001; Hirtz et al., 2007).
It is usually fatal in less than 3 years after the onset of symptoms
due to paralysis of the respiratory muscles, and is frequently
accompanied by cognitive impairment. ALS can be divided into two
categories, with 90e95% of cases are termed sporadic ALS (sALS)
and 5e10% termed familial ALS (fALS). Mutations in the protein
copperezinc superoxide dismutase (SOD1), an antioxidant protein,
are involved in 15e20% of the cases of fALS (Dion et al., 2009).
The pathophysiology of ALS is unknown but there are several
interesting hypotheses. The discovery of mechanisms of ALS is
complicated by what appears to be multiple candidates for etiology
including inﬂammation, oxidative stress, mitochondrial dysfunc-
tion, aberrant RNA processing, misfolding and aggregation of pro-
teins, disruption of axon guidance, glutamate excitotoxicity, and
dysregulation of neurotrophic factors. Moreover, no decision has
yet been reached onwhether the UMN or LMN is the primary site of
disease, or whether “variants” effecting only upper or only lower
motor neurons are all the same or different diseases (Redler and
Dokholyan, 2012). Environmental factors may have a role in the
disease (Redler and Dokholyan, 2012).
In both fALS and sALS, the spinal cord of patients contain SOD1-
positive proteinaceous inclusions when examined post-mortem.
Patients with sALS and fALS also reveal Lewy body-like hyaline in-
clusions (LBHI) that stain positive for SOD1 (Shibata et al., 1994,
1996; Matsumoto et al., 1996; Watanabe et al., 2001; Stathopulos
et al., 2003). LBHIs are also seen in Parkinson’s disease,
Fig. 6. Upper and lower motor neurons. The upper motor neuron is shown on the left descending from the brain to the spinal cord. The lower motor neuron, shown on the right,
descends from the spinal cord to the muscle.
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2001). The SOD1 polypeptide is composed of 153 nucleotides, and
160 mutations in the polypeptide have been linked to ALS (World
Federation Of Neurology And European Network To Cure ALS,
2013). The amino acid sequence in wild-type SOD1 protein in mice
and humans is 84% identical. One proposed mechanism is a “gain of
function toxicity” induced by the mutations, which results in the
protein SOD1 aggregating and misfolding. SOD1-rich proteinaceous
deposits have been discovered in humans and the SOD1 mouse
(Gurney et al., 1994; Wong et al., 1995; Bruijn et al., 2004; Cozzolino
et al., 2008). The original research linking SOD1 to ALS was human-
based (Deng et al., 1993; Rosen et al., 1993), with the SOD1 mouse
model being developed in 1994 (Gurney et al., 1994). Mitochondria
were implicated in ALS secondary to human tissue research using
microscopic staining in 1966 (Aﬁﬁ et al., 1966). The main neuro-
pathological ﬁndings are illustrated in Table 5 (Kato, 2008).
SOD1 is conserved among species. For example, the three-
dimensional structure of SOD1 (a protein dimer) is conserved
among yeast (Djinovic et al., 1992; Ogihara et al., 1996; Hart et al.,
1999), frogs (Djinovic Carugo et al., 1996), cows (Tainer et al.,
1982; Rypniewski et al., 1995), and humans (Parge et al., 1992;
Banci et al., 2006; Strange et al., 2006). Moreover, according to
Seetharaman et al.: “In mammals, 112 of 153 residues [are]
conserved across species and 70 residues are invariant across
eukaryotic phyla. Sixty-one of the pathogenic mutations occur at
residues conserved in mammals, with 49 occurring at positions
that are ‘extremely conserved’ ” (Seetharaman et al., 2010).
Seetharaman et al., continue, stating: “Given this high degree ofsequence identity [84%], it might be expected that mouse SOD1
would be prone to co-aggregate with mutant human SOD1 in
transgenic mice and in cell culture. However... endogenous mouse
SOD1 was not a component of these aggregates (Wang et al., 2003;
Lambrechts et al., 2009). In contrast, humanwild-type SOD1, when
coexpressed in mice with the pathogenic SOD1 variants A4V, G85R,
G93A, and L126Z, was found co-aggregated with the pathogenic
SOD1 variants in the detergent insoluble fractions of spinal cord
lysates coming from these animals (Deng et al., 2006; Wang et al.,
2009)” (Seetharaman et al., 2010).
Wild-type SOD1 from humans increased disease severity in
mouse models, in addition to other changes (Deng et al., 2006;
Wang et al., 2009). That the 16% difference in sequence identity is
highly signiﬁcant is not unanticipated. As we discussed in the
section on evolution, even one SNP can have lethal ramiﬁcations
(Seetharaman et al., 2010). Differences also exist in the number of
copies of the gene. The SOD1 transgene mouse with a G93A mu-
tation exhibits up to 25 copies of the transgene. This results in a
large amount of SOD1 protein produced. A variant of G93A contains
fewer copies and exhibits a slower disease course. Differences have
also been demonstrated between sexes of mice and among mice
with different genetic backgrounds (Acevedo-Arozena et al., 2011).
Changes like copy number variations (CNVs) and nucleotide
sequence variations, and the inﬂuence of background genes, are
why speciation results in two species that are differently complex
and thus we should expect differences in response to perturbations.
There are numerous differences among strains of the SOD1
mice, including differences secondary to background genes (Kato,
Table 5
Summary of main neuropathological ﬁndings in autopsied patients with familial amyotrophic lateral sclerosis (FALS) with characteristic mutations of superoxide dismutase 1
(SOD1) (Kato, 2008) (for references see Kato, 2008.)
SODl mutation Number of patients Neuronal inclusion SODl aggregation Bunina body Corticospinal tract involvement Posterior column involvement
A4V 3 LBHI þ  þ(slight) þ
5 ICI ND ND (mild) þ(asymmetry)
A4T 1 LBHI þ  þ(mild) þ
G37R 1 LBHI þ  þ þ
H43R 1 LBHI þ  þ þ
H46R 1 LBHI þ  þ(very mild) þ(very mild)
H48Q 1 LBHI&SL1   þ(mild) minimal
E100G 1 SLI  ND þ þ
D101N 2 ICHI ND ND  
D101Y 1 LBHI þ  þ(very mild) 
LI 06 V 2 LBHI þ  þ þ
C111Y 1 LBHI þ  þ Minimal
I113T 1 NFT ND ND þ 
(Brain and brain stem)
1 ICAI ND ND  ND
1 ICAI þ  ND ND
1 HC ND ND þ þ
1 NFCI   þ(slight) þ
L126S 1 LBHI þ  þ þ
2-bp del 2 LBHI þ  þ(slight/marked) þ
(L126dellTT) 1 LBHI þ  þ 
C146R 2 LBHI þ  þ(slight) þ
Wild type 2 SLI/RHI  þ þ 
As controls, FALS siblings with wild-type SOD1 are also tabulated in the bottom row þ, present;  absent.
ND: not described; LBHI: Lewy body-like hyaline inclusion; ICI: intracytoplasmic inclusion; SLI: skein-like inclusion; RHI: round hyaline inclusion; ICHI: intracytoplasmic
hyaline inclusion; NFT: neuroﬁbrillary tangle (straight ﬁlament); ICAI: intracytoplasmic argyrophilic inclusion (neuroﬁlament accumulation); HC: hyaline conglomerate (with
neuroﬁlament epitope); NFCI: neuroﬁlamentous conglomerate inclusion; bp, base pair; del deletion.
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A4V mutation represents approximately 50% of all patients with
fALS and is associated with a more rapid course. In the SOD1mouse
however, the A4Vmutation results in no neurodegeneration during
the normal lifespan of the mouse. When the SOD1 A4V mouse is
also carrying the wild-type SOD1, then aggressive neuro-
degeneration is seen (Deng et al., 2006). A similar situation is
observed with mutations G93A and LI26Z (Bruijn et al., 1998;
Jaarsma et al., 2008), but no such difference is noted for the mu-
tation G85R (Bruijn et al., 1998). Chattopadhyay and Valentine
state: “These differences indicate that transgenic mice homozygous
for speciﬁc mutants do not necessarily reﬂect aggregation trends
and hence, disease mechanisms, observed in fALS patients who are
usually heterozygous” (Chattopadhyay and Valentine, 2009).
Moreover, when this many differences exist among strains of the
same species, we should not expect the model to have predictive
value for a different species. Evolved CASs simply do not allow for
this many differences without a high probability of dramatic
changes in outcomes to perturbations.
Statements like the following by Seetharaman et al., are typical
of the claims regarding the SOD1 mouse model: “Although ALS is a
human disease, the development of transgenic mouse models that
retain many of the pathological features found in human ALS have
been extremely valuable” (Seetharaman et al., 2010).
Seetharaman et al., discuss the optimism surrounding the discovery
of SOD1 and the value of using the SOD1 mouse in order to provide
new treatments for ALS. However, they then conclude: “Although a
large number of pathogenic SOD1 proteins have been studied
intensely by many laboratories over years... the precise molecular
mechanism(s) through which these proteins exert their toxic ef-
fects remain to be delineated” (Seetharaman et al., 2010). Chatto-
padhyay and Valentine likewise state: “Transgenic mice expressing
mutations in the SOD1 gene have been invaluable tools to inves-
tigate disease mechanisms and possible therapeutic applications in
ALS” (Chattopadhyay and Valentine, 2009). Yet, they too acknowl-
edge the failure of themodel: “However, failure to translate positivepreclinical ﬁndings achieved in these mice into positive clinical
trials in ALS patients has raised concerns about the relevance of
SOD1 mouse models to ALS...” (Chattopadhyay and Valentine,
2009).
Pan et al., continue the praise of the SOD1 mouse, stating:
“Creation of transgenic mice expressing mutant Cu/Zn superoxide
dismutase (SOD1), as ALS models, has made an enormous impact
on progress of the ALS studies.... Genetically engineered mice have
played a pivotal role not only in the molecular pathogenesis but
also in the development of therapeutics for many genetic as well as
non-genetic diseases. Indeed, the creation of ALS animal models,
namely transgenic mice expressing a mutant SOD1, has made an
enormous impact on progress of the ALS studies” (Pan et al., 2012).
Rothstein writes: “Transgenic mouse models with mutations in the
SOD1 gene and other ALS genes develop pathology reminiscent of
the disorder, including progressive death of motor neurons, and
have provided insight into the pathogenesis of the disease but have
consistently failed to predict therapeutic efﬁcacy in humans”
(Rothstein, 2009). Peviani et al., state: “[SOD1 mouse models]
replicate many of the clinical, neuropathological and molecular
features of ALS patients and have contributed signiﬁcantly to our
understanding of the pathogenic mechanisms of this disease.
Although results obtained so far with mutant SOD1 mice have not
translated into effective therapies in ALS patients, thesemodels still
represent the only experimentally accessible system to study
multiple aspects of disease pathogenesis and to provide proof-of-
principle for the development of new therapeutic strategies”
(Peviani et al., 2010).
Thus we note that the claims for the SOD1mouse are strong and
supportive, yet some simultaneously admit that clinical progress
has been slow to nonexistent. This is oxymoronic nevertheless
typical of the animal model literature in general. Despite failure
after failure of the model in question to aid patients suffering from
the disease, advocates of the model make strong claims regarding
its value. We acknowledge that animal models such as the SOD1
mouse have aided in advancing science but so has the study of
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with advances in medicine.
Benatar, who reinforces Giles’ comment above, is another
example: “The scientiﬁc and ethical justiﬁcation for animal models
of human disease is that they may provide an opportunity to
investigate disease biology and to identify potential therapies that
might be beneﬁcial to humans” (Benatar, 2007). However, Benatar
follows this by noting the scientiﬁc success of the SOD1 mouse,
stating: “The most popular animal model of amyotrophic lateral
sclerosis (ALS) is the mouse that has been genetically engineered to
express a mutant form of the human superoxide dismutase (SOD1)
gene. The most commonly used SOD1mouse harbors the glycine to
alanine mutation at amino acid 93 (G93A). Since the identiﬁcation
of mutations in the SOD1 gene as an important cause of familial ALS
and the generation of the SOD1 mouse model of ALS several years
later, there have been dozens of studies of a panoply of therapeutic
agents in SOD1 mice. The choice of therapeutic agents in many
clinical trials of human ALS has been predicated, at least in part, on
the efﬁcacy of these drugs when studied in the SOD1 mouse”
(Benatar, 2007).
Benatar then acknowledges the clinical success has been less
impressive: “Nevertheless, success in human clinical trials has been
extremely limited, calling into question the utility of such preclin-
ical data for identifying therapeutic agents that are worthy of
further study in humans” (Benatar, 2007). Scott et al., reinforce
Benatar, stating: “Identiﬁcation of SOD1 as the mutated protein in a
signiﬁcant subset of familial amyotrophic lateral sclerosis (FALS)
cases has led to the generation of transgenic rodent models of
autosomal dominant SOD1 FALS. Mice carrying 23 copies of the
human SOD1G93A transgene are considered the standard model
for FALS and ALS therapeutic studies. To date, there have been at
least 50 publications (see Nirmalananthan and Greensmith, 2005
and Rothstein, 2004) describing therapeutic agents that extend
the lifespan of this mouse. However, no therapeutic agent besides
riluzole has shown corresponding clinical efﬁcacy” (Scott et al.,
2008).
The drug riluzole is the only current treatment that extends life,
although only marginally, in ALS patients (Corcia and Gordon,
2012) and it was not discovered because of the SOD1 mouse. Cor-
cia and Gordon note that every drug tested after riluzole has failed
in humans (see Table 6 for a list of some of these drugs.). These
drugs have included antiglutamatergics, antiapoptotics, anti-
inﬂammatories, immune modulators, and protein-clearing agents
(Corcia and Gordon, 2012). However, they then state that “basic and
clinical research methods in ALS have become dramatically more
sophisticated.” They describe the drug Dexpramipexole (RPPX), the
R(þ) enantiomer of pramipexole, stating that it has the “largest
body of pre- and early clinical data that support testing in ALS.... The
investigators can be conﬁdent that they are proceeding with a drugTable 6
Clinical failures on ALS drugs (Corcia and Gordon, 2012).
Drug Trial design Mechanism
Glatiramer Phase III Immune modulator
Lithium Phase II Antiglutamatergic, Protein clearanc
Ceftriaxone Phase IIeIII Antiglutamatergic
Memantine Phase II Antiglutamatergic
Arimoclomol Phase II Heat shock protein inducer
Talampanel Phase II Antiglutamatergic
CoQl0 Phase II dose selection/futility Antioxidant/mitochondrial cofactor
Minocycline Phase III Anti-inﬂammatory/antiapoptotic
Xaliproden Phase III Antiapoptotic
Gabapentin Phase III Antiglutamatergic
Celecoxib Phase III Anti-inﬂammatory
Riluzole Phase III Antiglutamatergic, unknown
Abbreviation: ALSFRS-R, revised version of the Amyotrophic Lateral Sclerosis Functionalthat is ready for efﬁcacy testing” (Corcia and Gordon, 2012). RPPX
was efﬁcacious in the SOD1 mouse model as well as other species
(Danzeisen et al., 2006; Corcia and Gordon, 2012). RPPX failed,
however, in Phase III human clinical trials (the EMPOWER study)
that ended in December 2012, secondary to lack of efﬁcacy (Jeffrey,
2013). Biogen Idec discontinued the Phase III trials involving 943
patients because none showed any improvement. Kerr, of Biogen
Idec, states: “Quite simply the drug did not work, not on any
measure” (Sinha, 2013).
Despite the above evidence, Kato states: “Of course, human ALS
and all ALS animal models share one most important similarity in
that both exhibit motor neuron degeneration/death. This important
point of similarity has shed much light on the pathomechanisms of
the motor neuron degeneration/death at the cellular andmolecular
levels that would not have been appreciated if only human ALS
autopsy samples had been available” (Kato, 2008). In light of the
failures of the SOD1 mouse to predict human response to thera-
peutics, on what basis does Kato conclude the pathophysiology
between humans and the mouse model are the same? There are
two possibilities:
1. Human data exists to support the claim, in which case the data
could have been derived from human-based research without
the animal models.
2. Kato is merely making an assumption that has not been shown
true.
Both possibilities reveal an unwarranted conﬁdence that animal
models are the best way to discover human pathophysiology. We
will continue this examination in the following section on rebuttals
to our position.
3.6. Response to defenses of animal models
As we have shown, despite the empirical evidence and theory in
the form of evolution and CASs, scientists continue to defend the
SOD1 model, and animal models in general, as being of predictive
value for human response to disease and drugs. Peviani et al., state:
“Animal models are an invaluable experimental paradigm to
examine the multiple aspects of the pathogenesis of a neurode-
generative disease, particularly when many cellular systems are
involved as in ALS” (Peviani et al., 2010). Fomchenko and Holland
express conﬁdence in animal models when they state: “GEMs
[genetically engineered mice] closely recapitulate the human dis-
ease and are used to predict human response to a therapy, treat-
ment or radiation schedule.... GEMs that faithfully recapitulate
human brain tumors and will likely result in high-quality clinical
trials with satisfactory treatment outcomes and reduced drug
toxicities. Additional use of GEMs [include the ability] to establishSample Endpoint Outcome
360 ALSFRS-R Negative
e Up to 171 Survival/ALSFRS-R Negative
600 Survival/ALSFRS-R Ongoing
63 ALSFRS-R Negative
84 Safety Adequate safety
59 Arm strength Nonsigniﬁcant improvement
185 ALSFRS-R Negative
412 ALSFRS-R Negative
Up to 1210 Survival Breathing capacity Negative
204 Arm strength Negative
300 Arm strength Negative
Up to 959 Survival Positive
Rating Scale.
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and brain tumor initiation...” (Fomchenko and Holland, 2006). Such
examples could be easily multiplied.
Despite the evidence, many in the scientiﬁc community simply
will not accept that there is anything of scientiﬁc concern regarding
animal models. Most of the scientists we have encountered, espe-
cially in the biological sciences but also in the physical sciences,
express the same sentiment the authors of the Seok paper, referred
to in Section 3.2, encountered when presenting their data. Kolata
writes: “The [Seok] study’s investigators tried for more than a year
to publish their paper, which showed that therewas no relationship
between the genetic responses of mice and those of humans. They
submitted it to the publications Science and Nature, hoping to reach
a wide audience. It was rejected from both” (Kolata, 2013). Kolata
then quotes RW Davis, a coauthor of the Seok article, who said:
“reviewers did not point out scientiﬁc errors... the most common
response was, ‘It has to be wrong. I don’t know why it is wrong, but
it has to be wrong’ ” (Kolata, 2013).
“It has to be wrong.” That is exactly the response we have
received from the biomedical research community when we have
published our position on modeling evolved CASs (Greek and
Pound, 2002; Greek and Shanks, 2009, 2011; Shanks and Greek,
2009; Shanks et al., 2009; Greek and Greek, 2010; Greek et al.,
2011a,b, 2012a,b; Greek and Hansen, 2012; Greek and Rice, 2012).
The reviewers, and ultimately the readers, do not present counter-
arguments or point out errors of fact. They offer no data to invali-
date our claims nor do they offer theoretical considerations from
complexity science or evolutionary biology. They simply do not
accept the empirical evidence or theoretical underpinning. Here,
we respond to some of the arguments or claims that have been
made, as they are relevant to the arguments we have presented in
this article.
Many of the arguments against our position are in the form of
unsupported claims. In the summary from the March 28 and 29,
2012, workshop on Animal Models for Nervous System Disorders,
held in Washington, D.C., the authors state: “Ferrante [Professor in
the departments of neurological surgery, neurology, and neurobi-
ology at the University of Pittsburgh] suggested that current animal
models for Huntington’s disease and ALS may accurately reﬂect not
only pathophysiological mechanisms of human disease, but also
neuropathology and behavioral phenomena. For other disorders,
however, it is much more difﬁcult” (Pankevich et al., 2013). We
consider this article to have sufﬁciently refuted this claim,
although, to quote Christopher Hitchens: “What can be asserted
without evidence can also be dismissed without evidence”
(Hitchens, 2003). Scientists need to remember that the null hy-
pothesis still applies and that the burden of proof is on the one
making the claims regarding animal models.
Novella discusses the role of animal models, stating: “Mouse
and other animal models are essential to biomedical research. The
goal is to ﬁnd a speciﬁc animal model of a human disease and then
conduct preliminary research on the animal model in order to
determine which research is promising enough to study in
humans” (Novella, 2013a). Indeed, that is the goal. Implied in this
goal is the notion that animal models are, or can be, of predictive
value for humans in terms of responses to drugs and disease.
However, as we have shown, such a notion is simply without
support. Anecdotes offer nothing in terms of PPV and NPV, and
correlations that are only revealed retrospectively do not qualify as
being of predictive value. Thus the claim that animal models are
essential to biomedical research is a case of begging the question.
Nevertheless, most defenses of animal models begin just this way.
Novella continues: “I would also point out that it is highly
problematic to discuss the utility of animal models in general. Each
animal model needs to be considered by itself, in terms of howpredictive it is, and for what. For example, there are SOD1micewho
have a mutation that causes familial ALS (FALS). This mouse model
has served as a screen for many potential ALS treatments” (Novella,
2013a). Novella neglects to state that all of these potential treat-
ments failed in humans. The National Cancer Institute thinks so-
ciety may have lost cures for cancer due to animal screening (Gura,
1997), and other scientists have expressed similar concerns
regarding other diseases (Weatherall, 1982; Editorial, 2003;
Lazzarini et al., 2006). It is not impossible that ALS patients have
lost treatments because of animal screening. In terms of the value
of animal models in general, we can evaluate the predictive value of
animal models as they are currently used, and where such data are
available PPVs around 0.3 seem to the norm (Litchﬁeld, 1962, 1965;
Fletcher, 1978; Heywood, 1990; Lumley, 1990; Suter, 1990; Spriet-
Pourra and Auriche, 1994). The PPV for neuroprotection, treat-
ments for ALS, cancer, and sepsis as well as a vaccine against HIV,
among others, currently have a PPV of zero. When science is eval-
uating perturbations that occur at lower levels of organization, for
example whether an antibiotic will kill a bacterium, animal models
do have predictive value. In some of these cases however, so do
petri dishes. When studying perturbations that occur at lower
levels of organization, animal models have been important. With
few exceptions, diseases and drugs do not act at these levels. An-
tibacterials are affecting a different system, namely the wall of the
bacterium, and this can be evaluated without animal models. The
CAS in question in terms of efﬁcacy is the bacterium, not the animal
infected by it.
Novella continues: “It turns out that the SOD1 mouse is an
excellent animal model for SOD1 FALS in humans. This is not sur-
prising considering that it is the same mutation. However, the SOD1
mousemodel of ALS is much less predictive for sporadic ALS.Most of
the drugs that look promising in the SOD1 model have not shown a
signiﬁcant clinical effect in humanswith sporadic ALS (only one drug
has actually made it through FDA approval: riluzole)” (Novella,
2013a). Novella, a neurologist who treats ALS, is arguably in a
reasonable position to judge the value of an animal model. However,
as we should anticipate from the section on evolution, mutations do
not result in the same outcomes across species lines. For example,
mutations that cause phenylketonuria and Sanﬁlippo syndrome in
humans are normal in macaque monkeys (Gibbs et al., 2007;
Holmes, 2007). As we stated, even strains of the same species vary
in their response to seemingly potent perturbations such as knock-
ing out a gene. Combine this with convergent evolution and we see
no reason to suspect conservation of gene function across species.
Conservation does happen (Greek and Rice, 2012), but there seems to
be no standard method for determining it without comparative
studies. Thus again we can only establish validity in retrospect.
Novella’s comment also raises the question: what makes an
animal model excellent? If all treatment attempts based on the
model have failed in humans, then that alone is sufﬁcient to suggest
the model is not even useful as a heuristic (functioning as a guide in
discovery or investigation) and certainly not an excellent model.
Schnabel, writing in 2008 observed that even then around a dozen
drugs had been reported to prolong life in the SOD1 mouse model
but none were effective in humans with ALS. As an example,
Schnabel cites the antibiotic minocycline, which was efﬁcacious in
SOD1 mouse models in four different labs. Minocycline not only
failed in humans but made the symptoms of ALS worse in a trial
with 400 patients (Schnabel, 2008).
Why did the treatments referred to by Schnabel fail in humans if
the model is even adequate? There could be several explanations:
1. The model predicted safety not efﬁcacy. However, the SOD1
mouse did predict efﬁcacy in many of the treatments and ef-
ﬁcacy is precisely why the drugs failed in humans.
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from the SOD1 mouse. Perhaps mice and humans share several
modules that are involved in ALS, but if even one module dif-
fers, then, because both mice and humans are evolved CASs,
perturbations to the same module could lead to different out-
comes. Therefore, a treatment could be successful mice but fail
in humans. However, this would also invalidate the notion of
the SOD1 mouse as an excellent model of predictive value.
3. All the modules of ALS pathophysiology are shared by the SOD1
mouse and humans but the background and modiﬁer genes
differ, thus placing us back to our theme that small differences
between evolved CASs result in the same perturbation giving
rise to different responses.
Further, to claim the pathophysiology of ALS is the same in the
SOD1 mouse as it is in humans is again a case of begging the
question, as the pathophysiology has not been determined in
humans. However, let’s assume that the general pathophysiology of
ALS in the SOD1 mouse mimics that of fALS in humans. What does
that achieve in terms of predicting human response to treatments?
Very little, as even if mice and humans share all the modules, the
modules interact with other modules and with the organism as a
whole, thus the same perturbation/drug can affect the two species
very differently. Very small differences between evolved CASs can
negate a large number of similarities when using one evolved CAS
to predict outcomes for a second. Additionally, even if the patho-
physiology is identical, we still have the problem of emergent
properties and the whole being greater than the sum of its parts.
Novella then discusses the Seok (Seok et al., 2013) paper, which
investigated gene response to sepsis, burns, and blunt trauma, and
found little correlation between species: “The deeper question isd
how similar is the mouse immune system to the human immune
system” (Novella, 2013a). As we discussed above, no animal model
is going to be similar enough to the human system to allow a high
PPV and NPV. This is because of differences in initial conditions in
terms of genes, genetic regulation and expression, and gene net-
works. Emergent phenomenon, redundancy and robustness, and
other characteristics of evolved CASs will also affect predictive
value. Moreover, evolved CASs are also dynamic so we observe
differences due to changes in the genome via epigenetics (Mueller
and Olsson, 2003; Flintoft, 2005; Fraga et al., 2005; Qiu, 2006;
Gosden and Feinberg, 2007; Ballestar, 2010; Javierre et al., 2010b;
Meymandi, 2010; Bell and Spector, 2011; Brower, 2011; Gordon
et al., 2011; Czyz et al., 2012). Even monozygotic twins fail to
respond in the same fashion to diseases like multiple sclerosis and
schizophrenia, and small changes in the genome may explain why
this is the case (Herndon and Jennings, 1951; Alexanderson and
Borga, 1972; Lin et al., 1989; Fraga et al., 2005; Wong et al., 2005;
Bruder et al., 2008; Muqit et al., 2008; Javierre et al., 2010a;
Misch et al., 2010; Stankiewicz and Lupski, 2010; Bell and Spector,
2011; Dempster et al., 2011; Gordon et al., 2011; Maiti et al., 2011;
Ollikainen and Craig, 2011; Chapman and Hill, 2012; Czyz et al.,
2012; Halder et al., 2012; Zhao et al., 2012).
Novella recognizes the importance of predictive value. On the
podcast Skeptics Guide to the Universe, February 9, 2013 (beginning
at 1:09:09 into the broadcast), he discusses the predictive values of
diagnostic tests. Novella states, we need to pay more attention to
“statistical predictability, the base rate and how predictive things
are... I’ll tell medical students, don’t worry about whether or not
this symptom is typical of this disease. I want to know how pre-
dictive it is that this is the diagnosis” (Novella, 2013b). In light of the
above we fail to understand how he can consider animal models,
especially the SOD1 mouse, to be of predictive value.
Novella concludes his comments on the Seok paper stating: “The
current research appears to be a signiﬁcant blow to the currentmouse models of inﬂammatory stress, but also contains a wealth of
information about which genes become active in humans and mice
in response to such stress. This potentially can lead to other useful
models or biomarkers, and also to new treatments in this very
challenging area of medicine” (Novella, 2013a). Part of this state-
ment is a tautology. If one wishes to draw conclusions about the
similarities and differences among species, then comparative
research is mandatory. But that is not what researchers using ani-
mal models usually claim, as we pointed out in the preceding
sections. The SOD1 mouse does appear to mimic humans in terms
of some of the characteristics of ALS. While interesting, this does
not mean the same mechanisms are involved for reasons alluded to
in the section on evolution. The SOD1 mouse has failed in terms of
predicting treatment success and we suspect it will do the same for
biomarkers. Even if a treatment or biomarker is eventually found
because of the SOD1 mouse, the numerous failures will translate to
a PPV that is far from adequate in terms of considering it to be of
predictive value.
Theory derived from complexity science and evolutionary
biology supports the empirical ﬁndings that animal models can
only be identiﬁed retrospectively as responding to perturbations,
like drugs and disease, as humans responded. Hau pointed this out
years ago: “It is not possible to give reliable general rules for the
validity of extrapolation from one species to another. This has to be
assessed individually for each experiment and can often only be
veriﬁed after ﬁrst trials in the target species [humans]” [(Hau,
2003) p. 6]. This appears to invalidate the concept of animals as
predictive models for human response to drugs and disease, and we
are left with using animals as heuristic devicesd a source for new
ideasd a use for which they are scientiﬁcally valid. It also appears
to invalidate the notion that wemust evaluate animalmodels one at
a time as advocated by Novella and others. Furthermore, evenwhen
an animal is discovered that responds to, say, a teratogen, as
humans respond, it rarely responds like humans to other terato-
gens (Greek et al., 2011b). So again, one instance of correlation is an
anecdote, not a model with predictive value.
Applying Complexity Theory and the Theory of Evolution to the
problem of using one evolved CAS as a model in order to predict
responses of a second has resulted in what one of us (Greek) has
called Trans-Species Modeling Theory (TSMT): While trans-species
extrapolation is possible when perturbations concern lower levels
of organization or when studying morphology and function on the
gross level, one evolved complex system will not be of predictive
value for another when the perturbation affects higher levels of
organization. TSMT fulﬁlls Popper’s criteria for a theory (Popper,
2002).
1. It is supported by a vast amount of evidence. Where direct
comparisons are possibled such as with drug toxicity, efﬁcacy,
bioavailability, and so forth d deﬁnitive evidence exists to
support the concerns raised by trans-species modeling theory
(In addition to the previously cited references see (Greek, 2008,
2012, 2013a,b; Greek and Shanks, 2009; Shanks and Greek,
2009; Shanks et al., 2009; Greek et al., 2011b, 2012a; Greek
and Rice, 2012.) If two evolved CASs are not predictive for
each other in these areas, what changes in evolution would
account for their being predictive in other areas such as HIV,
ALS, and cancer? Indeed the empirical evidence in these areas
agrees with that from the drug development literature.
2. The prediction that such systems should not be of predictive
value contained risk in that evolution has followed common
pathways and therefore many similarities should and do exist.
Based on TSMT, we should expect agreement among species
when the perturbation affects only the lower levels of the hi-
erarchy of organization (for example, the laws of physics affect
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levels of organization the perturbations should be expected to
result in varying responses both qualitatively as well as quan-
titatively (see (Shanks and Greek, 2009; Greek and Rice, 2012)
for more on this.). Empirically, we ﬁnd those two predictions
are fulﬁlled.
3. It prohibits animal models from predictive value at higher
levels of organization and this has been quantiﬁed.
4. It is refutable. For example, a species or strain that correlated
with human data regarding known teratogens >95% of the
time and that correctly predicted novel teratogens a similar
percentage of the time would falsify the theory.
5. It has been tested many times in disciplines ranging from in-
fectious diseases, cancer, toxicity, neurology, and drug efﬁcacy
to teratogenicity.
6. Conﬁrming evidence has come from many and varied disci-
plines involved in animal use: research on heart disease, sepsis,
trauma, and anesthesiology.
7. The theory is straightforward and has no ad hoc features.
Suggesting that animal models must be evaluated on a case-by-
case basis is like asking that each ﬂora or fauna that ﬁlls an
ecological niche be evaluated for achieving its position through an
act of special creation or evolution. There is no logical reason to
assume the trait in questionwas not the result of a special creation.
But in light of theory d the Theory of Evolution d and empirical
evidence, there is no reason to ask such questions. Theories and
laws in science prohibit certain hypotheses. For example, the Germ
Theory of Disease prohibited, and indeed replaced, the notion that
rotting organic matter caused diseasedmiasma. The Germ Theory
does not prohibit other causes of disease, such as cancer, vascular
abnormalities, and endocrine disorders, but it does mandate the
clinician consider bacteria and viruses instead of rotting matter.
Likewise, Atomic Theory prohibits an inﬁnite division of matter into
smaller and smaller units, and the Theory of Relativity prohibits
faster-than-light velocities.
We should also note, yet again, what we are not saying. In an
article proclaiming the value of animal models in basic research,
Carbone stated that Greek and Greek (2004): “would end animal
studies, which they ﬁnd misleading to the point of danger d a
‘scientiﬁc failure’ ”(Carbone, 2012). On the contrary, Greek et al.,
have stated exactly the opposite many times. For example, Shanks
and Greek: “This book is not intended to be a criticism of the use of
animals in the context of basic biological research. There can be no
doubt that careful studies of animals have prompted important
hypotheses about basic biological principles, and there can be no
doubt that studies of animals have contributed greatly to our sci-
entiﬁc understanding of life, and there is little doubt that these
studies will continue to illuminate these matters in the future... ”
[(Shanks and Greek, 2009) p. 30].
What Greek et al., have consistently stated is that animal models
have no predictive value in terms of human response to drugs and
disease. For example, Shanks and Greek: “The purpose of this book
is to address the ability, or lack thereof, of animals to predict human
response and to see what other roles theymay have in research and
testing. We will argue that claims concerning the great utility of
animals as predictive models of human biomedical phenomena are
unsupported by evidence and are compromised by both method-
ological issues and issues arising from basic biological theory”
[(Shanks and Greek, 2009) p. 24].
Carbone’s argument is thus a straw man. Gorski also commits
this fallacy: “In other words, because animal models have many
difﬁculties and ﬂaws and all too often don’t predict human physi-
ology or drug response as well as the critics think that they should,
then by implication all animal research is bad science” (Orac, 2010).Stemwedel also resorts to a straw man: “Ray Greek, president of
Americans for Medical Advancement... asserted that animals are
too different from humans to tell us anything useful about humans,
and suggested that this is why so few basic research studies end up
resulting in knowledge or therapies that are useful in treating hu-
man patients” (Stemwedel, 2010).
The argument we have presented regarding the SOD1 mouse is
representative of outcomes from animal models. Occasionally an
animal will mimic humans in response to a perturbation at higher
levels of organization. But this happens at a rate that approaches
what we would expect from random chance and hence cannot be
consider of predictive value. Moreover, even in retrospect it is
difﬁcult to reproduce some aspects of human responses to drugs
and disease (Rosenblum et al., 1965a,b,c; Collins et al., 1969;
Stolley, 1972; Stolley and Schinnar, 1979; Inman, 1980; Wynn,
1982; Bari, 1996; Gad, 2006). Because animals and humans are
evolved CASs, animal models per se will never be of predictive
value for responses to perturbations that occur at higher levels of
organization. This conclusion is not threatened if a drug is
discovered tomorrow that cures sepsis or AIDS in humans and in a
strain of mouse or a monkey. In order for a model to be of pre-
dictive value it must have a high PPV and NPV. It would also
facilitate matters if we knew why the model worked when all
others do not. Similarities in responses between humans and
animal models have, to date, been haphazard and not repeatable
for other drugs or species. As stated earlier, if the only way a
scientist can know whether the model will reproduce outcomes
for humans is in retrospect, then the model has no predictive
value.
4. Conclusions
Grove states: “Humans are incredibly complex biological sys-
tems, and working with them has to be subject to safety, legal, and
ethical concerns.... The result is wide-scale experimentation with
animal models of dubious relevance, whose merit principally lies in
their short lifespan” (Grove, 2005). Humans and animals have a
genome, proteome, transcriptome, interactome, metabolome, reg-
ulome, and epigenome and they all interact and modify one
another. Understanding the interactions is crucial in a complex
system.
Current science has advanced to the place where we are asking
very speciﬁc questions, the answers to which can only be deter-
mined by studying humans with speciﬁc genotypes. Medical
practice, as well as medical research, is aiming for personalized
medicine. The reasons individual humans respond differently to
perturbations such as drugs and disease are qualitatively the
same reasons different species respond differently. Any two
evolved complex adaptive systems are unlikely to experience
identical outcomes to the same perturbation provided the
perturbation occurs at higher levels of organization. Responses to
drugs and disease occur at these higher levels and this accounts
for the profound inter-species variation we describe. Modeling
one evolved CAS (animals) in order to predict responses to drugs
and disease for a second CAS (humans) is not scientiﬁcally viable
based on the best science we currently have. Trans-species
modeling theory accounts for both the successes and failures of
animal models and has been veriﬁed empirically in a wide variety
of areas. That having been stated, animal models have been very
useful as a heuristic and in outlining the general contours of
mammalian physiology and of life itself. Early studies on animals
revealed facts that would have been difﬁcult to obtain without
animal use.
Trans-species modeling theory has major implications for the
use of animal models in research.
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